No black box warning on record for 6% Hetastarch In 0.9% Sodium Chloride

As of the latest FDA labeling reviewed, 6% Hetastarch In 0.9% Sodium Chloride (6% HETASTARCH IN 0.9% SODIUM CHLORIDE) does not carry a black box warning. Standard warnings and precautions still apply — see the full 6% Hetastarch In 0.9% Sodium Chloride medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS 5.1 Renal Dysfunction • Avoid use in patients with pre-existing renal dysfunction • Discontinue use of 6% Hetastarch in 0.9% Sodium Chloride Injection at the first sign of renal injury • Continue to monitor renal function in hospitalized patients for at least 90 days as use of RRT has been reported up to 90 days after administration of HES products, including 6% Hetastar

No black box warning on record for 6% Hetastarch In 0.9% Sodium Chloride

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS 5.1 Renal Dysfunction • Avoid use in patients with pre-existing renal dysfunction • Discontinue use of 6% Hetastarch in 0.9% Sodium Chloride Injection at the first sign of renal injury • Continue to monitor renal function in hospitalized patients for at least 90 days as use of RRT has been reported up to 90 days after administration of HES products, including 6% Hetastar

6% Hetastarch In 0.9% Sodium Chloride Black Box Warning

No black box warning on record for 6% Hetastarch In 0.9% Sodium Chloride

Other warnings & precautions

6% Hetastarch In 0.9% Sodium Chloride Black Box Warning

No black box warning on record for 6% Hetastarch In 0.9% Sodium Chloride

Other warnings & precautions